Alert-based ePRO monitoring just got randomised controlled trial evidence, and the results are hard to ignore.
A randomised controlled trial published in JAMA Oncology, the PRO B study, followed 909 patients with metastatic breast cancer across 52 German breast centres. The intervention was deliberately simple: weekly ePRO questionnaires delivered through an app, automated alerts when scores showed clinically meaningful decline, and care-team follow-up within 48 hours.
What it delivered: a clinically meaningful reduction in fatigue at six months, sustained through twelve. Improved physical functioning against usual care. And a signal on 12-month survival, a secondary endpoint, but one that warrants attention.
The takeaway is the one we build for. ePROs aren't just data collection. When responses trigger timely clinical action, they become clinical intelligence, surfacing deterioration before the next scheduled visit and routing the patient's voice to the right clinician at the right moment. It's the same alert-based model TCP runs across our digital care pathways: systematic patient-reported data, read and acted on like any clinical instrument.